Publications

Polyclonal Pulmonary Tuberculosis Infections and Risk for Multidrug Resistance, Lima, Peru.

Author(s): Nathavitharana RR, Shi CX, Chindelevitch L, Calderon R, Zhang Z, Galea JT, Contreras C, Yataco R, Lecca L, Becerra MC, Murray MB, Cohen T|Journal: Emerg Infect Dis|PMID: 29048297| November 2017

Because within-host Mycobacterium tuberculosis diversity complicates diagnosis and treatment of tuberculosis (TB), we measured diversity prevalence and associated factors among…

Projecting the benefits of antiretroviral therapy for HIV prevention: the impact of population mobility and linkage to care.

Author(s): Andrews JR, Wood R, Bekker LG, Middelkoop K, Walensky RP|Journal: J Infect Dis|PMID: 22711905| August 2012

Recent mathematical models suggested that frequent human immunodeficiency virus (HIV) testing with immediate initiation of antiretroviral therapy (ART) to individuals…

The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: a model-based analysis.

Author(s): Andrews JR, Lawn SD, Rusu C, Wood R, Noubary F, Bender MA, Horsburgh CR, Losina E, Freedberg KA, Walensky RP|Journal: AIDS|PMID: 22333751| May 2012

In settings with high tuberculosis (TB) prevalence, 15-30% of HIV-infected individuals initiating antiretroviral therapy (ART) have undiagnosed TB. Such patients…

Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis.

Author(s): Andrews JR, Noubary F, Walensky RP, Cerda R, Losina E, Horsburgh CR|Journal: Clin Infect Dis|PMID: 22267721| March 2012

The risk of progression to active tuberculosis is greatest in the several years following initial infection. The extent to which…